Amplia Therapeutics Limited
Amplia Therapeutics Limited (ATX.AX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Amplia Therapeutics Limited (ATX.AX), covering cash flow, earnings, and balance sheets.
Amplia Therapeutics Limited (ATX.AX) Income Statement & Financial Overview
View the income breakdown for Amplia Therapeutics Limited ATX.AX across both annual and quarterly reports.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $1.41M | $2.004M | $2.45M | -$579895.00 |
| Cost of Revenue | $71023.00 | $330574.00 | $42949.00 | $44376.00 |
| Gross Profit | $1.34M | $1.67M | $2.41M | -$624271.00 |
| Gross Profit Ratio | $0.95 | $0.84 | $0.98 | $1.08 |
| R&D Expenses | $2.80M | $3.61M | $2.19M | $1.16M |
| SG&A Expenses | $1.34M | $1.43M | $1.37M | $1.59M |
| Operating Expenses | $4.09M | $5.02M | $3.57M | $2.75M |
| Total Costs & Expenses | $4.17M | $5.35M | $3.61M | $2.80M |
| Interest Income | $0.00 | $66550.00 | $78551.00 | $83491.00 |
| Interest Expense | $0.00 | $31849.00 | $46632.00 | $37705.00 |
| Depreciation & Amortization | $43361.00 | $43200.00 | $42949.00 | $44376.00 |
| EBITDA | -$2.80M | -$3.44M | -$1.12M | -$2.67M |
| EBITDA Ratio | -$1.99 | -$1.72 | -$0.46 | $4.75 |
| Operating Income | -$2.76M | -$3.34M | -$3.61M | -$2.80M |
| Operating Income Ratio | -$1.96 | -$1.67 | -$1.47 | $4.82 |
| Other Income/Expenses (Net) | -$55226.00 | -$2.02M | $31919.00 | $45786.00 |
| Income Before Tax | -$2.81M | -$5.36M | -$3.58M | -$2.75M |
| Income Before Tax Ratio | -$2.000 | -$2.68 | -$1.46 | $4.74 |
| Income Tax Expense | $0.00 | -$1.99M | -$2.45M | $579895.00 |
| Net Income | -$2.81M | -$3.37M | -$1.13M | -$3.33M |
| Net Income Ratio | -$2.000 | -$1.68 | -$0.46 | $5.74 |
| EPS | -$0.01 | -$0.02 | -$0.006 | -$0.02 |
| Diluted EPS | -$0.01 | -$0.02 | -$0.006 | -$0.02 |
| Weighted Avg Shares Outstanding | $253.55M | $193.79M | $199.62M | $199.62M |
| Weighted Avg Shares Outstanding (Diluted) | $253.70M | $194.006M | $199.62M | $199.62M |
The company's financials show resilient growth, with revenue advancing from -$579895.00 in Q4 2023 to $1.41M in Q2 2025. Gross profit remained healthy with margins at 95% in Q2 2025 compared to 108% in Q4 2023. Operating income hit -$2.76M last quarter, sustaining a consistent -196% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$2.80M. Net income rose to -$2.81M, while earnings per share reached -$0.01. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan